Medifast, Inc. (MED) is likely to register a decrease in both top and bottom lines when it reports third-quarter 2024 earnings on Nov. 4. The Zacks Consensus Estimate for revenues is pegged at $135.5 million, which indicates a 42.6% decline from the year-ago period.The consensus mark for the bottom line has remained unchanged in the past 30 days at a loss of 15 cents, indicating a substantial decline from the prior-year quarter’s $2.12. MED has a trailing four-quarter earnings surprise of 64.5%, on average ...